miRoncol Health Launches AI Cancer Screening Blood Test in Ontario
miRoncol Health announced in a press release the launch of miCheckup, a miRNA blood test for multi cancer screening in Ontario. The service is available to eligible adults who have no cancer symptoms and costs CAD $1,299.
The test profiles microRNA molecules in a blood sample, then uses an AI algorithm to identify patterns associated with cancer. Customers request the test through a private virtual clinic, receive a requisition from a qualified practitioner when appropriate, and provide a blood sample at LifeLabs.
If the test detects a suspected cancer signal, the price covers a private whole body MRI when the scan is suitable and available through a participating facility. The company says a positive signal is not a cancer diagnosis, and customers should continue recommended screening and medical care regardless of the result.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
MediSights Reports Study Using AI Agents for Myeloma Market Research
QC Healthcare Partners With Sanguina for AI Blood Health Screening
SimBioSys Gets FDA Clearance for AI Breast Cancer Recurrence Tool
Helio Genomics Presents Four HelioLiver Studies on Liver Cancer Detection
Gemini Health Partners Launches AI Revenue Cycle Advisory Service
Daily AI Brief: the AI news that matters, in your inbox.